

APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

APPENDIX A

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical name: Zinc and compounds
CAS number:
Date: May 6, 2005
Profile status: Final Draft Post-Public
Route: Inhalation Oral
Duration: Acute Intermediate Chronic
Key to figure: 25
Species: Human
MRL: 0.3 mg/kg/day ppm mg/m³

Reference: Yadrick MK, Kenney MA, Winterfelt EA. 1989. Iron, copper, and zinc status: Response to supplementation with zinc or zinc and iron in adult females. *Am J Clin Nutr* 49:145-150.

Experimental design: Eighteen healthy women, ages 25–40 years, were given zinc gluconate supplements twice daily (50 mg supplemental zinc/day, or 0.83 mg supplemental zinc/kg/day assuming a 60-kg mean body weight for healthy women) for a 10-week period (Yadrick et al. 1989). Blood was drawn from each subject prior to treatment for use as a referent. Erythrocyte superoxide dismutase (ESOD) activity declined over the 10-week supplementation period and, at 10 weeks, was significantly ($p < 0.05$) lower (47% decrease) than pretreatment values; a decrease at 6 weeks of exposure (15%) was not statistically significant. ESOD levels are considered to be a sensitive indicator of systemic copper status. Ceruloplasmin levels were not altered. Serum zinc was significantly increased at both 6 and 10 weeks. There was also a significant decline in serum ferritin (23%) and hematocrit (4%) values at 10 weeks. In women similarly-exposed but also receiving 0.42 mg supplemental iron/day, serum ferritin was increased at both 6 and 10 weeks of exposure, while serum ESOD levels were significantly decreased at 6 weeks (24%) and 10 weeks (47%).

Effects noted in study and corresponding doses: Statistically significant decreases in erythrocyte SOD and serum ferritin levels at 0.83 mg supplemental zinc/kg/day. Since these effects were subclinical, they were designated as non-adverse, as described below.

Dose end point used for MRL derivation: Yadrick et al. (1989) reported a significant decrease in ESOD, which is considered to be a sensitive indicator of body copper status, in women exposed to 50 mg supplemental zinc/day. Because the observed effect is considered to be a precursor event to the more severe symptoms seen with zinc-induced copper deficiency, rather than a toxic effect of itself, the 50 mg supplemental zinc/day value is considered to be NOAEL. At the same exposure level, serum ferritin levels decreased from 36.6 to 28.2 $\mu\text{g/L}$ (23% decrease), which was statistically significant. According to the most recent NHANES data (cited in IOM 2000), the median range for serum ferritin levels in menstruating women is 36–40 $\mu\text{g/L}$, while a value of $<12 \mu\text{g/L}$ represents depleted iron stores. Thus, the subjects dropped below the median range for women of their age group, but were still considerably above the level that would represent a depletion of iron stores; in the absence of other effects indicating changes in iron status, this subclinical effect was also designated as a NOAEL. Assuming a reference female body weight of 60 kg, this represents 0.83 mg zinc/kg/day.

NOAEL LOAEL

APPENDIX A

Uncertainty factors used in MRL derivation:

1 3 10 (for use of a LOAEL)
 1 3 10 (for extrapolation from animals to humans)
 1 3 10 (for human variability)

The intermediate oral MRL for zinc is derived as follows:

$$\begin{aligned} \text{MRL} &= \text{NOAEL} \div \text{UF} \\ \text{MRL} &= 0.83 \text{ mg zinc/kg/day} \div 3 \\ \text{MRL} &= 0.3 \text{ mg zinc/kg/day} \end{aligned}$$

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

Was a conversion used from intermittent to continuous exposure? If so, explain: No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Other additional studies or pertinent information that lend support to this MRL:

It should be noted that the MRL is calculated based on the assumption of healthy dietary levels of zinc (and copper), and represents the level of exposure above and beyond the normal diet that is believed to be without an appreciable risk of toxic response.

Fischer et al. (1984) gave groups of 13 healthy adult male volunteers (ages not specified) 0 (cornstarch) or 25 mg supplemental zinc (as zinc gluconate) twice daily for 6 weeks (0 or 0.71 mg supplemental zinc/kg/day). Nonfasting blood samples were taken at the beginning and at biweekly intervals and tested for measures of copper status. ESOD activity decreased after 4 weeks in the supplement group and was significantly lower than controls by 6 weeks. An inverse correlation between plasma zinc levels and erythrocyte superoxide dismutase activity was also observed at 6 weeks. Plasma copper levels and levels of ferroxidase activity did not change during the course of the study.

Groups (n=10–13) of postmenopausal women (mean age 64.9±6.7 years) with an average body weight of 65.1±9.5 kg were evaluated for the effects of excess zinc exposure (Davis et al. 2000; Milne et al., 2001). After an initial equilibration period during which they received 2 mg Cu and 9 mg zinc/day (the RDA for women of that age is 8 mg zinc/day) for 10 days, subjects received either low (1 mg) or high (3 mg) copper diets, and either low (3 mg) or high (56 mg) zinc for 90 days; it is noteworthy that the “low copper” subjects were still receiving copper levels greater than the current RDA for copper. After a 10-day equilibration period, the study was repeated with the same copper level in the diet, such that each subject received both low and high zinc throughout the course of the study. Blood was drawn during each equilibration period, and twice monthly during the exposure periods. Levels during the equilibration periods were used as the referent for the exposure periods. Zinc supplementation resulted in significant increases in plasma and platelet zinc levels. In high-zinc subjects, increases were seen in bone-specific alkaline phosphatase levels (~25%) and extracellular superoxide dismutase (~15%), while significant decreases were seen in mononuclear white cell 5'-nucleotidase (~30%) and plasma 5'-nucleotidase activity (~36%). Slight (<10%) changes were also seen in erythrocyte copper/zinc SOD and plasma free thyroxine. Other evaluated end points were not significantly modified by zinc supplementation. Copper status indicators were decreased by supplementation with zinc, including copper balance (total intake-total eliminated in urine and feces), serum-immunoreactive ceruloplasmin, platelet

APPENDIX A

cytochrome-c oxidase activity, total cholesterol, glutathione, and glutathione peroxidase activity. No effect was seen on concentration of zinc in red blood cells or on indicators of iron status.

Groups of 9, 13, or 9 healthy white men were administered 0, 50, or 75 mg/day supplemental zinc as zinc gluconate (total zinc intakes were 0.16, 0.85, and 1.10 mg supplemental zinc/kg/day, respectively, based on mean group body weights) for 12 weeks (Black et al. 1988). The subjects were given instructions to avoid foods high in calcium, fiber, and phytic acid, dietary constituents that are known to decrease zinc absorption. Subjects were also told to restrict their intake of zinc-rich foods in order to minimize the variation in daily dietary zinc. There was a general decline in the mean serum HDL-cholesterol for the 75-mg supplement group between weeks 6 and 12. HDL values for this group were significantly lower than those for the placebo group at weeks 6 and 12 ($p < 0.05$). There was also a decline in the HDL values for the 50-mg group between weeks 8 through 12; however, this decline was not significantly different from that for the controls until the 12th week of treatment. Serum zinc, copper, total cholesterol, LDL-cholesterol, and triglycerides did not appear to be affected by treatment.

Freeland-Graves et al. (1982) exposed groups of eight healthy women to 0, 15, 50, or 100 mg supplemental zinc as zinc acetate (approximately 0, 0.25, 0.83, or 1.7 mg supplemental zinc/kg/day, assuming a reference female body weight of 60 kg) daily for 60 days. In the highest exposure group only, plasma HDL-cholesterol was significantly reduced at 4 weeks of exposure, but not at any other timepoint examined. A correlation between dietary zinc and whole-blood copper was observed in treated subjects. In the 50 and 100 mg groups, some bloating, nausea, and abdominal cramps were reported unless the supplement was taken with a large glass of water at mealtime.

Prasad et al. (1978) fed a patient with sickle cell anemia supplements of 150–200 mg supplemental zinc/day for 2 years. The supplement resulted in copper deficiency; serum copper and plasma ceruloplasmin levels were decreased. When copper was administered, the plasma ceruloplasmin levels became normal. In a follow-up study, of 13 patients on zinc therapy (similar treatment levels assumed), 7 patients had ceruloplasmin levels at the lower limit of normal after 24 weeks of dosing.

Agency Contact (Chemical Managers): Nickolette Roney, M.S.; Cassandra V. Smith, M.S.; Malcolm Williams, D.V.M., Ph.D.

APPENDIX B. USER'S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not

APPENDIX B

meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

Chapter 3

Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

APPENDIX B

LEGEND**See Sample LSE Table 3-1 (page B-6)**

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system,

APPENDIX B

which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

- (9) **LOAEL.** A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) **Reference.** The complete reference citation is given in Chapter 9 of the profile.
- (11) **CEL.** A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) **Footnotes.** Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

LEGEND

See Sample Figure 3-1 (page B-7)

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) **Exposure Period.** The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) **Health Effect.** These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) **Levels of Exposure.** Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.
- (16) **NOAEL.** In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) **CEL.** Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

APPENDIX B

- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q_1^*).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

SAMPLE

1 →

Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation

Key to figure ^a	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
					Less serious (ppm)	Serious (ppm)	
INTERMEDIATE EXPOSURE							
	5	6	7	8	9		10
3 →	Systemic	↓	↓	↓	↓	↓	↓
4 →	18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 ^b	10 (hyperplasia)	Nitschke et al. 1981
CHRONIC EXPOSURE							
	Cancer					11	
					↓		
	38	Rat	18 mo 5 d/wk 7 hr/d			20	(CEL, multiple organs) Wong et al. 1982
	39	Rat	89–104 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, nasal tumors) NTP 1982
	40	Mouse	79–103 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, hemangiosarcomas) NTP 1982


12 →

^a The number corresponds to entries in Figure 3-1.

^b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5×10^{-3} ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

SAMPLE

Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation



APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD	benchmark dose
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CL	ceiling limit value
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor
DOT	Department of Transportation

APPENDIX C

DOT/UN/ NA/IMCO	Department of Transportation/United Nations/ North America/International Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F ₁	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K _d	adsorption ratio
kg	kilogram
kgg	metric ton
K _{oc}	organic carbon partition coefficient
K _{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC ₅₀	lethal concentration, 50% kill
LC _{Lo}	lethal concentration, low
LD ₅₀	lethal dose, 50% kill
LD _{Lo}	lethal dose, low
LDH	lactic dehydrogenase
LH	lutinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT ₅₀	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid
MAL	maximum allowable level
mCi	millicurie
MCL	maximum contaminant level

APPENDIX C

MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration
OSW	Office of Solid Waste, EPA
OTS	Office of Toxic Substances
OW	Office of Water

APPENDIX C

OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SIC	standard industrial classification
SIM	selected ion monitoring
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
TD ₅₀	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization

APPENDIX C

>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q ₁ *	cancer slope factor
-	negative
+	positive
(+)	weakly positive result
(-)	weakly negative result

APPENDIX D. INDEX

absorbed dose.....	94
active transport.....	82
adenocarcinomas.....	68
adipose tissue.....	178
adrenal gland.....	90
adsorbed.....	139, 152, 153, 155, 157, 169, 184
adsorption.....	139, 153, 155, 156, 157, 160, 201
aerobic.....	152
ambient air.....	32, 163, 177
anaerobic.....	153, 156, 160
anemia.....	5, 13, 15, 17, 19, 34, 58, 59, 69, 88, 95, 98, 102, 107, 110, 111, 113, 202
bioaccumulation.....	139, 188
bioavailability.....	79, 99, 184, 187, 188
bioconcentration factor.....	158
bioconcentration factors.....	158
biomarker.....	93, 94, 95, 96, 111
biomarkers.....	93, 94, 96, 111, 117, 191, 202, 204
body weight effects.....	24, 63
breast milk.....	142, 179
cancer.....	4, 13, 37, 67, 92, 210
carcinogenic.....	12, 13, 16, 22, 38, 67, 68
carcinogenicity.....	5, 13, 68, 106, 109, 210
carcinoma.....	38
cardiovascular.....	33, 39, 57, 69, 167
cardiovascular effects.....	32, 33, 39, 57
chromosomal aberrations.....	73, 109
clearance.....	13, 33, 75, 77
crustaceans.....	139, 177, 184
death.....	22, 23, 24, 38, 39, 69, 92, 104
deoxyribonucleic acid (see DNA).....	21, 74
dermal effects.....	62, 69, 72, 93
DNA (see deoxyribonucleic acid).....	21, 31, 74, 94, 98, 100, 109
dopamine.....	15
endocrine.....	24, 62, 89
endocrine effects.....	62
ferritin.....	18, 19, 58, 97, 108, 205
fetus.....	81, 91, 92
gastrointestinal effects.....	13, 33, 34, 57, 58
general population.....	11, 93, 100, 141, 176, 181
genotoxic.....	22, 109
genotoxicity.....	98, 106, 109
groundwater.....	3, 141, 151, 157, 163, 173, 183, 210
growth retardation.....	11, 21, 92
half-life.....	77, 93
hematological effects.....	34, 58, 59, 69, 108
hepatic effects.....	34, 60, 61
hydrolysis.....	160
immune system.....	63, 95, 110

APPENDIX D

immunological	17, 22, 63, 106
immunological effects.....	106
K_{ow}	125, 126, 127, 128
LD_{50}	38, 39, 107
lymphoreticular	63
mass spectroscopy.....	192
metabolic effects	39
metal fume fever	4, 12, 14, 16, 29, 30, 34, 35, 36, 88, 95, 103, 106, 107, 110, 113, 177
milk	79, 81, 101, 177, 178, 185, 187, 191, 192
mucociliary	13, 33
musculoskeletal effects	60
neurobehavioral.....	89
nuclear.....	116, 159
ocular effects	35, 62, 104
pharmacodynamic	84
pharmacokinetic	84, 85, 86, 91
photolysis	160
placenta	67, 81
pulmonary fibrosis	32, 103
renal effects	35, 61
retention	77, 84, 88, 111, 188
solubility	38, 75, 116, 153, 156, 160, 184, 187, 188
superoxide dismutase	11, 15, 17, 18, 21, 58, 98, 108, 117, 205
T3	62
T4	62, 63
thyroid.....	116
thyroid stimulating hormone (see TSH).....	62
toxicokinetic.....	21, 75, 108, 112
toxicokinetics	112
TSH (see thyroid stimulating hormone).....	62, 63
tumors	68, 98, 100
weanling.....	60